FDA Approves New Pancreatic Cancer Pill | Charleston News

FDA just approved a groundbreaking daily pill, Rasonque, for advanced pancreatic cancer patients — offering new hope where options were scarce. Targeting the RAS protein that fuels tumor growth, the drug extended median survival to over 13 months versus 7 months with standard chemo. Fast-tracked and even made available early to desperate patients, it’s a major leap forward for a disease often caught too late. Side effects like rash and fatigue are possible, but this approval signals real progress in the fight against one of medicine’s toughest cancers. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6a53f76fea073557